Phospho-PLCG1 (Tyr771) Antibody

What is PLCG1 and what is the significance of its phosphorylation at Tyrosine 771?

Phospholipase C gamma 1 (PLCG1) is a key signaling enzyme that belongs to the mammalian Phospholipase C gamma family, which includes two closely related proteins: PLCG1 and PLCG2. PLCG1 contains core structural domains plus a unique array of domains including an additional PH domain, two SH2 domains, and one SH3 domain .

When activated through phosphorylation, PLCG1 catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to produce two critical second messenger molecules: inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) . These second messengers subsequently trigger calcium release and protein kinase C activation.

Phosphorylation at Tyrosine 771 (Tyr771) is one of several critical regulatory phosphorylation sites on PLCG1. Research has shown that phosphorylation at Tyr771 has regulatory effects on PLCG1 activity, although interestingly, studies with PDGF-responsive cells indicated that substitution of Tyr771 with phenylalanine actually increased PDGF-dependent activation of PLCG1 .

How do PLCG1 phosphorylation sites (Tyr771, Tyr783, and Tyr1253) differ in their functions?

PLCG1 undergoes phosphorylation at multiple tyrosine residues, with distinct functional outcomes:

Studies have shown that growth factor receptor engagement (like PDGF or EGF receptors) or T-cell receptor (TCR) stimulation leads to rapid phosphorylation of PLCG1 at these sites. While Tyr783 is essential for activation, and Tyr1253 is needed for maximal stimulation, phosphorylation at Tyr771 appears to have a more complex regulatory function that may be context-dependent .

What species reactivity can be expected with commercially available Phospho-PLCG1 (Tyr771) antibodies?

Commercially available Phospho-PLCG1 (Tyr771) antibodies show varying degrees of species cross-reactivity, which is an important consideration for experimental design:

When selecting an antibody, researchers should consider not only the species reactivity but also the intended application, as some antibodies are optimized for specific techniques such as Western blotting, immunohistochemistry, or immunofluorescence .

How should researchers validate the specificity of Phospho-PLCG1 (Tyr771) antibodies?

Validation of antibody specificity is crucial for reliable experimental results. For Phospho-PLCG1 (Tyr771) antibodies, consider the following validation approaches:

• Phosphatase treatment control: Treat half of your sample with lambda phosphatase to remove phosphorylation. A specific phospho-antibody should show diminished or absent signal in the phosphatase-treated sample.

• Stimulation experiments: Compare samples from cells in basal states versus those stimulated with growth factors known to induce PLCG1 phosphorylation (e.g., EGF, PDGF). The antibody should detect increased phosphorylation in stimulated samples .

• Knockout/knockdown validation: Use PLCG1-deficient cell lines like the J.gamma1 Jurkat T-cell line (which contains no detectable PLCG1 protein) as a negative control .

• Peptide competition: Pre-incubate the antibody with a phospho-Tyr771 peptide, which should block specific binding and eliminate the signal if the antibody is specific.

• Cross-validation with other phosphorylation sites: Compare phosphorylation patterns detected with antibodies against other PLCG1 phosphorylation sites (e.g., Tyr783, Tyr1253) to build a complete profile of PLCG1 activation status .

What are the optimal protocols for using Phospho-PLCG1 (Tyr771) antibodies in Western blotting?

For optimal Western blotting results with Phospho-PLCG1 (Tyr771) antibodies, follow these methodological recommendations:

• Sample preparation:

  • Lyse cells in buffer containing phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride)

  • Maintain samples at 4°C throughout processing

  • Use freshly prepared samples when possible to prevent phospho-epitope degradation

• Dilution ratio:

  • Most commercial Phospho-PLCG1 (Tyr771) antibodies perform optimally at 1:1000 dilution for Western blotting

  • Always perform a dilution series to determine optimal concentration for your specific experimental system

• Detection system:

  • Use horseradish peroxidase-coupled secondary antibodies

  • Enhanced chemiluminescence reagents provide sensitive detection

• Expected molecular weight:

  • PLCG1 runs at approximately 155 kDa on SDS-PAGE gels

  • Confirm specificity by observing a single band at the expected molecular weight

• Positive controls:

  • Lysates from cells stimulated with EGF or PDGF serve as excellent positive controls

What cell types and experimental models are most suitable for studying PLCG1 Tyr771 phosphorylation?

The choice of experimental model is critical for studying PLCG1 Tyr771 phosphorylation. Based on research findings, these models have proven valuable:

• Cell lines:

  • Jurkat T-cell lines: The P98 and J.gamma1 sublines (with reduced or absent PLCG1 expression) are useful for reconstitution studies

  • PDGF-responsive fibroblasts: Demonstrate robust PLCG1 phosphorylation in response to growth factor stimulation

  • Endothelial cells: Show distinctive patterns of PLCG1 phosphorylation in developmental and angiogenic contexts

• Animal models:

  • Zebrafish: Valuable for studying PLCG1 phosphorylation during vascular development

  • Mouse models: Useful for tissue-specific activation patterns, although complete PLCG1 knockout is embryonically lethal

• Primary cells:

  • T lymphocytes: Excellent for studying TCR-dependent phosphorylation of PLCG1

  • Endothelial cells: Allow investigation of vascular-specific PLCG1 phosphorylation patterns

What are common challenges when detecting phosphorylated PLCG1 (Tyr771) and how can they be addressed?

Researchers frequently encounter these challenges when working with Phospho-PLCG1 (Tyr771) antibodies:

• Weak or absent signal:

  • Ensure cells were properly stimulated with appropriate growth factors

  • Verify phosphatase inhibitors were included in lysis buffers

  • Consider increasing antibody concentration or incubation time

  • Use fresh lysates to prevent phospho-epitope degradation

• Non-specific bands:

  • Increase blocking time and washing steps

  • Optimize antibody dilution (start with manufacturer recommendations)

  • Use 5% BSA rather than milk for blocking and antibody dilution

  • Consider increasing the stringency of wash buffers

• Inconsistent results:

  • Standardize cell stimulation protocols

  • Establish consistent timing between stimulation and lysis

  • Use internal loading controls such as GAPDH

  • Normalize phospho-PLCG1 signal to total PLCG1 expression

• High background:

  • Optimize blocking conditions

  • Increase wash duration and frequency

  • Reduce primary and secondary antibody concentrations

  • Consider using alternative detection systems

How should samples be prepared to preserve PLCG1 phosphorylation status?

Preserving phosphorylation status is critical for accurate detection of Phospho-PLCG1 (Tyr771). Follow these methodological recommendations:

• Cell harvesting:

  • Work quickly and maintain samples at 4°C

  • Avoid unnecessary delays between stimulation and lysis

  • For adherent cells, consider direct lysis on the plate

• Lysis buffer composition:

  • Include multiple phosphatase inhibitors (e.g., 1 mM sodium orthovanadate, 10 mM sodium fluoride, 10 mM β-glycerophosphate)

  • Add protease inhibitors to prevent protein degradation

  • Use a buffer with adequate detergent concentration (e.g., 1% NP-40 or Triton X-100)

• Sample storage:

  • Aliquot samples to avoid freeze-thaw cycles

  • Store at -80°C for long-term storage

  • Add sample buffer and heat denature just before gel loading

• Tissue samples:

  • Flash-freeze tissues in liquid nitrogen immediately after collection

  • Consider preservation methods like phospho-fixatives if performing immunohistochemistry

  • Homogenize tissues in buffer containing phosphatase inhibitors at 4°C

How does PLCG1 Tyr771 phosphorylation contribute to developmental processes versus pathological conditions?

PLCG1 Tyr771 phosphorylation exhibits distinct patterns in developmental versus pathological contexts:

• Developmental processes:

  • In zebrafish embryos, Phospho-PLCG1 (Tyr771) is observed in endothelial cells lining the dorsal aorta (DA) and intersegmental vessels (ISV), but not the posterior cardinal vein (PCV)

  • This pattern suggests a specific role in arterial differentiation and angiogenesis during normal development

  • PLCG1 knockout in mice results in early embryonic lethality, indicating essential developmental functions

• Pathological conditions:

  • Aberrant PLCG1 signaling contributes to various pathological processes

  • In T-cell activation disorders, TCR-dependent phosphorylation of PLCG1 at multiple sites (including Tyr771) plays a crucial role in disease progression

  • PLCG1 phosphorylation status in tumor angiogenesis may differ from developmental angiogenesis patterns

• Tissue-specific patterns:

  • Unlike some other signaling molecules (e.g., PKA, PKC) that show activity in all blood vessels, PLCG1 phosphorylation displays vessel type-specific patterns

  • This specificity suggests PLCG1 phosphorylation as a potential biomarker or therapeutic target for vessel-specific interventions

What is the relationship between PLCG1 Tyr771 phosphorylation and downstream signaling pathways in different cellular contexts?

The relationship between PLCG1 Tyr771 phosphorylation and downstream signaling pathways is complex and context-dependent:

• T-cell receptor signaling:

  • In T-cells, PLCG1 phosphorylation couples TCR ligation to interleukin-2 (IL-2) gene expression

  • Studies with PLCG1-deficient Jurkat T-cell lines (P98 and J.gamma1) revealed that PLCG1 deficiency causes profound defects in TCR-dependent calcium mobilization and NFAT activation

  • PLCG1 requires functional SH2 domains and specific phosphorylation sites for optimal signaling

• Receptor tyrosine kinase signaling:

  • Growth factor receptors (e.g., PDGF, EGF) trigger phosphorylation of PLCG1 at multiple sites including Tyr771

  • In PDGF-responsive cells, Tyr771 phosphorylation may have an inhibitory effect, as mutation to phenylalanine enhanced PDGF-dependent activation

• Vascular development:

  • Intriguingly, Phospho-PLCG1 is observed throughout arterial and intersegmental vessel endothelial cells, but ERK phosphorylation occurs only in sprouting cells

  • This suggests that PLCG1 phosphorylation is necessary but not sufficient for ERK activation and that additional regulatory mechanisms exist

• Signaling complex formation:

  • Beyond its enzymatic role, phosphorylated PLCG1 may serve as a scaffold for assembling multimolecular signaling complexes

  • Both amino- and carboxyl-terminal SH2 domains are required for optimal PLCG1 phosphorylation and activation

Understanding these complex relationships provides opportunities for targeted therapeutic interventions in diseases characterized by dysregulated PLCG1 signaling.